ArticleOpen respiratory archives
[Consensus document for severe asthma in adults. 2022 update].
Article in Open respiratory archives. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Beyond biomarkers: the role of clinical factors associated with biologic therapy response in severe asthma.Annals of medicine · 2026Observational
- Bridging the Knowledge Gap: Transforming COPD Management Through Lessons from Asthma.Pulmonary therapy · 2026Review
- Real-World Effectiveness of Tezepelumab in Severe Asthma: A Comparative Analysis of High and Low T2 Phenotypes.Journal of personalized medicine · 2026Article
- Effectiveness of Mepolizumab in Severe Uncontrolled Asthma Associated or Not with EGPA Based on the Exacto Scale and Separ-Remas Criteria.Journal of asthma and allergy · 2026Article
- Real-World Response to Dupilumab as Add-on Therapy in Adults and Adolescents with Type 2 Severe Asthma: A Spanish Cohort Study.Journal of asthma and allergy · 2026Article
- Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab.Allergy · 2025Article
- Early and Sustained Clinical Benefits of Benralizumab in Severe Eosinophilic Asthma: Findings from the ORBE II Study.Journal of clinical medicine · 2025Article
- Efficacy Assessment of Biological Treatments in Severe Asthma.Journal of clinical medicine · 2025Review
- Monoclonal antibodies in severe asthma: outcomes from real-world data.Frontiers in medicine · 2025Article
- Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.Annals of medicine · 2024Article
- Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis.Journal of clinical medicine · 2024Article
- Evaluation Checklist for the Multidisciplinary Approach to Patients with Asthma or Suspected Asthma in United Airway Disease.Journal of asthma and allergy · 2024Article
- Editorial: A multidisciplinary approach to treatment of severe chronic airway disease (CAD): focus on biomarkers.Frontiers in allergy · 2024Article
- Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.Respiratory research · 2023Article
- Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype.International journal of molecular sciences · 2023Observational
- Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma.Journal of asthma and allergy · 2022Article
- Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach.Frontiers in allergy · 2022Article
- Real-life cost-effectiveness of benralizumab in patients with severe asthma.Respiratory research · 2021Article
- Enhancing the Management of Severe Asthma in Spain: The CARABELA Initiative Disclosed.Open respiratory archivesArticle
- Correlation of gastro-esophageal reflux disease with asthma control and quality of life: a cross-sectional study from a low-middle income country.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe asthma is a heterogeneous syndrome with several clinical variants and often represents a complex disease requiring a specialized and multidisciplinary approach, as well as the use of multiple drugs. The prevalence of severe asthma varies from one country to another, and it is estimated that 50% of these patients present a poor control of their disease. For the best management of the patient, it is necessary a correct diagnosis, an adequate follow-up and undoubtedly to offer the best available treatment, including biologic treatments with monoclonal antibodies. With this objective, this consensus process was born, which began in its first version in 2018, whose goal is to offer the patient the best possible management of their disease in order to minimize their symptomatology. For this 2020 consensus update, a literature review was conducted by the authors. Subsequently, through a two-round interactive Delphi process, a broad panel of asthma experts from SEPAR and the regional pulmonology societies proposed the recommendations and conclusions contained in this document.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.